{"protocolSection": {"identificationModule": {"nctId": "NCT00839800", "orgStudyIdInfo": {"id": "D589LC00001"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Investigate the Efficacy of Symbicort\u00ae SMART.", "officialTitle": "A Comparison of Symbicort\u00ae SMART (160/4.5\u03bcg) and Symbicort\u00ae Turbuhaler 160/4.5 \u03bcg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Study in Asthmatic Patients From 16 Years", "acronym": "SAKURA"}, "statusModule": {"statusVerifiedDate": "2012-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-02"}, "primaryCompletionDateStruct": {"date": "2011-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-02-04", "studyFirstSubmitQcDate": "2009-02-09", "studyFirstPostDateStruct": {"date": "2009-02-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-02-21", "resultsFirstSubmitQcDate": "2012-11-26", "resultsFirstPostDateStruct": {"date": "2012-11-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-11-26", "lastUpdatePostDateStruct": {"date": "2012-11-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5\u03bcg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5\u03bcg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Symbicort Turbuhaler"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 2091, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Symbicort Turbuhaler 160/4.5 \u00b5g one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 \u00b5g as needed", "interventionNames": ["Drug: Symbicort Turbuhaler"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Symbicort Turbuhaler 160/4.5 \u00b5g one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed", "interventionNames": ["Drug: Symbicort Turbuhaler", "Drug: Terbutaline Turbuhaler"]}], "interventions": [{"type": "DRUG", "name": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g", "armGroupLabels": ["1", "2"]}, {"type": "DRUG", "name": "Terbutaline Turbuhaler", "description": "0.4 mg", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study", "description": "Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid \\[GCS\\] treatment, hospitalization, or emergency room \\[ER\\] treatment.", "timeFrame": "week 52"}], "secondaryOutcomes": [{"measure": "Number of Asthma Exacerbations", "description": "Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.", "timeFrame": "up to 52 weeks"}, {"measure": "Morning Peak Expiratory Flow (PEF)", "description": "The mean value from a 52-week treatment period.", "timeFrame": "52-week treatment period"}, {"measure": "Evening PEF", "description": "The mean value from a 52-week treatment period.", "timeFrame": "2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period"}, {"measure": "Forced Expiratory Volume in One Second (FEV1)", "description": "The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.", "timeFrame": "4, 12, 24, 36 and 52 weeks after randomization"}, {"measure": "Use of As-needed Medication", "description": "The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).", "timeFrame": "52-week treatment period"}, {"measure": "Asthma Symptom Score", "description": "The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).", "timeFrame": "52-week treatment period"}, {"measure": "Nights With Awakening(s) Due to Asthma Symptoms", "description": "The mean value from the treatment period was presented here.", "timeFrame": "52-week treatment period"}, {"measure": "The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations", "description": "Mild asthma exacerbation was defined as morning PEF \u226520% below baseline, daily as-needed medication use \u22652 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.", "timeFrame": "up to 52 weeks"}, {"measure": "Symptom-free Days (no Symptoms and no Awakenings)", "description": "A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.", "timeFrame": "52-week treatment period"}, {"measure": "Percentage of As-needed-free Days", "description": "An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.", "timeFrame": "52-week treatment period"}, {"measure": "Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)", "description": "An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.", "timeFrame": "52-week treatment period"}, {"measure": "Asthma Control Questionnaire (ACQ)", "description": "The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.", "timeFrame": "4, 12, 24, 36 and 52 weeks after randomization"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of asthma according to the Global Initiative for Asthma guidelines (GINA) 2007 with a documented history of at least 6 months duration.\n* Reversible airway obstruction, defined as an increase in FEV1 \u226512% relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline Turbuhaler\n* Prescribed use of inhaled glucocorticoid steroid (GCS) (any brand) for at least 12 weeks.\n\nExclusion Criteria:\n\n* Respiratory infection affecting the asthma, as judged by the investigator, within 4 weeks.\n* Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Tomas Andersson, MD", "affiliation": "AstraZeneca R&D Lund", "role": "STUDY_DIRECTOR"}, {"name": "Tito Atienza, M.D.", "affiliation": "Mary Mediatrix Medical Center, Lipa City, Philippines", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Capital Federal", "state": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Mar Del Plata", "state": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Research Site", "city": "Monte Grande", "state": "Buenos Aires", "country": "Argentina"}, {"facility": "Research Site", "city": "Quilmes", "state": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.72904, "lon": -58.26374}}, {"facility": "Research Site", "city": "Rosario", "state": "Santa Fe", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Research Site", "city": "San Miguel de Tucuman", "state": "Tucuman", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Research Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad de Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Santa Fe", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Research Site", "city": "Porto Alegre", "state": "Brasil", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Belo Horizonte", "state": "MG", "country": "Brazil", "geoPoint": {"lat": -19.92083, "lon": -43.93778}}, {"facility": "Research Site", "city": "Juiz de Fora", "state": "MG", "country": "Brazil", "geoPoint": {"lat": -21.76417, "lon": -43.35028}}, {"facility": "Research Site", "city": "Rio de Janeiro", "state": "RJ", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "Research Site", "city": "Porto Alegre", "state": "RS", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Florianopolis", "state": "Santa Catarina", "country": "Brazil", "geoPoint": {"lat": -27.59667, "lon": -48.54917}}, {"facility": "Research Site", "city": "Santo Andre", "state": "SP", "country": "Brazil", "geoPoint": {"lat": -23.66389, "lon": -46.53833}}, {"facility": "Research Site", "city": "Shenyang", "state": "Liaoning", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Research Site", "city": "Hangzhou", "state": "Zhejiang", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Research Site", "city": "Chongqing", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "Research Site", "city": "Guang Zhou", "country": "China"}, {"facility": "Research Site", "city": "Nanjing", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Research Site", "city": "Qingdao", "country": "China", "geoPoint": {"lat": 36.06488, "lon": 120.38042}}, {"facility": "Research Site", "city": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Xi An", "country": "China"}, {"facility": "Research Site", "city": "Tres Rios", "state": "Cartago", "country": "Costa Rica", "geoPoint": {"lat": 9.90644, "lon": -83.9876}}, {"facility": "Research Site", "city": "Barrio San Bosco", "state": "San Jose", "country": "Costa Rica"}, {"facility": "Research Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Cegled", "country": "Hungary", "geoPoint": {"lat": 47.17266, "lon": 19.79952}}, {"facility": "Research Site", "city": "Debrecen", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "Research Site", "city": "Deszk", "country": "Hungary", "geoPoint": {"lat": 46.21802, "lon": 20.24322}}, {"facility": "Research Site", "city": "Gyula", "country": "Hungary", "geoPoint": {"lat": 46.65, "lon": 21.28333}}, {"facility": "Research Site", "city": "Nyiregyhaza", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Research Site", "city": "Szazhalombatta", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Research Site", "city": "Bangalore", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Research Site", "city": "Mangalore", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.91723, "lon": 74.85603}}, {"facility": "Research Site", "city": "Mysore", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.29791, "lon": 76.63925}}, {"facility": "Research Site", "city": "Trivandrum", "state": "Kerala", "country": "India", "geoPoint": {"lat": 8.4855, "lon": 76.94924}}, {"facility": "Research Site", "city": "Mumbai", "state": "Maharashtra", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Research Site", "city": "Nagpur", "state": "Maharashtra", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Research Site", "city": "Pune", "state": "Maharashtra", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "Research Site", "city": "Jaipur", "state": "Rajasthan", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "Research Site", "city": "Coimabatore", "state": "Tamilnadu", "country": "India"}, {"facility": "Research Site", "city": "Noida", "country": "India", "geoPoint": {"lat": 28.58, "lon": 77.33}}, {"facility": "Research Site", "city": "Komaki", "state": "Aichi", "country": "Japan", "geoPoint": {"lat": 35.28333, "lon": 136.91667}}, {"facility": "Research Site", "city": "Seto", "state": "Aichi", "country": "Japan", "geoPoint": {"lat": 35.23333, "lon": 137.1}}, {"facility": "Research Site", "city": "Asahi", "state": "Chiba", "country": "Japan", "geoPoint": {"lat": 35.71667, "lon": 140.65}}, {"facility": "Research Site", "city": "Matsuyama", "state": "Ehime", "country": "Japan", "geoPoint": {"lat": 33.83916, "lon": 132.76574}}, {"facility": "Research Site", "city": "Kitakyusyu", "state": "Fukuoka", "country": "Japan"}, {"facility": "Research Site", "city": "Yanagawa", "state": "Fukuoka", "country": "Japan", "geoPoint": {"lat": 33.16667, "lon": 130.4}}, {"facility": "Research Site", "city": "Isesaki", "state": "Gunma", "country": "Japan", "geoPoint": {"lat": 36.31667, "lon": 139.2}}, {"facility": "Research Site", "city": "ORA", "state": "Gunma", "country": "Japan"}, {"facility": "Research Site", "city": "Fukuyama", "state": "Hiroshima", "country": "Japan", "geoPoint": {"lat": 34.48333, "lon": 133.36667}}, {"facility": "Research Site", "city": "Hiroshima-shi", "state": "Hiroshima", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Research Site", "city": "Asahikawa", "state": "Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.77063, "lon": 142.36489}}, {"facility": "Research Site", "city": "Chitose", "state": "Hokkaido", "country": "Japan", "geoPoint": {"lat": 42.81944, "lon": 141.65222}}, {"facility": "Research Site", "city": "Sapporo", "state": "Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Research Site", "city": "Tomakomai", "state": "Hokkaido", "country": "Japan", "geoPoint": {"lat": 42.63694, "lon": 141.60333}}, {"facility": "Research Site", "city": "AKO", "state": "Hyogo", "country": "Japan"}, {"facility": "Research Site", "city": "Himeji", "state": "Hyogo", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "Research Site", "city": "Kobe-city", "state": "Hyogo", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Research Site", "city": "Hitachi", "state": "Ibaraki", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 140.65}}, {"facility": "Research Site", "city": "Naka-gun", "state": "Ibaraki", "country": "Japan", "geoPoint": {"lat": 36.05, "lon": 140.16667}}, {"facility": "Research Site", "city": "Morioka", "state": "Iwate", "country": "Japan", "geoPoint": {"lat": 39.7, "lon": 141.15}}, {"facility": "Research Site", "city": "Sakaide", "state": "Kagawa", "country": "Japan"}, {"facility": "Research Site", "city": "Kawasaki-shi", "state": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 35.52056, "lon": 139.71722}}, {"facility": "Research Site", "city": "Kawasaki", "state": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 35.52056, "lon": 139.71722}}, {"facility": "Research Site", "city": "Yokohama", "state": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Sendai", "state": "Miyagi", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "Research Site", "city": "Nagaoka", "state": "Niigata", "country": "Japan", "geoPoint": {"lat": 37.45, "lon": 138.85}}, {"facility": "Research Site", "city": "Beppu", "state": "Oita", "country": "Japan", "geoPoint": {"lat": 33.27945, "lon": 131.49751}}, {"facility": "Research Site", "city": "Kurashiki", "state": "Okayama", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 133.76667}}, {"facility": "Research Site", "city": "Sakai", "state": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 135.46667}}, {"facility": "Research Site", "city": "Matsue", "state": "Shimane", "country": "Japan", "geoPoint": {"lat": 35.48333, "lon": 133.05}}, {"facility": "Research Site", "city": "Utsunomiya", "state": "Tochigi", "country": "Japan", "geoPoint": {"lat": 36.56667, "lon": 139.88333}}, {"facility": "Research Site", "city": "Chuo", "state": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Research Site", "city": "Itabashi", "state": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Research Site", "city": "Kodaira", "state": "Tokyo", "country": "Japan"}, {"facility": "Research Site", "city": "Kokubunji", "state": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.70222, "lon": 139.47556}}, {"facility": "Research Site", "city": "Machida", "state": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.54028, "lon": 139.45083}}, {"facility": "Research Site", "city": "Nakano-ku", "state": "Tokyo", "country": "Japan", "geoPoint": {"lat": 36.75, "lon": 138.36667}}, {"facility": "Research Site", "city": "Toshima-ku", "state": "Tokyo", "country": "Japan"}, {"facility": "Research Site", "city": "Fukuoka", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Research Site", "city": "Kagoshima", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "Research Site", "city": "Kochi", "country": "Japan", "geoPoint": {"lat": 33.55, "lon": 133.53333}}, {"facility": "Research Site", "city": "Kyoto", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Research Site", "city": "Niigata", "country": "Japan", "geoPoint": {"lat": 37.88637, "lon": 139.00589}}, {"facility": "Research Site", "city": "Oita", "country": "Japan", "geoPoint": {"lat": 33.23333, "lon": 131.6}}, {"facility": "Research Site", "city": "Okayama", "country": "Japan", "geoPoint": {"lat": 34.65, "lon": 133.93333}}, {"facility": "Research Site", "city": "Bucheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Research Site", "city": "Cheongju", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "Research Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Suwon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Research Site", "city": "Kubang Kerian", "state": "Kelantan", "country": "Malaysia", "geoPoint": {"lat": 6.09123, "lon": 102.27938}}, {"facility": "Research Site", "city": "Kuantan", "state": "Pahang", "country": "Malaysia", "geoPoint": {"lat": 3.8077, "lon": 103.326}}, {"facility": "Research Site", "city": "Batu Caves", "state": "Selangor", "country": "Malaysia", "geoPoint": {"lat": 3.23333, "lon": 101.66667}}, {"facility": "Research Site", "city": "Kuala Lumpur", "country": "Malaysia", "geoPoint": {"lat": 3.1412, "lon": 101.68653}}, {"facility": "Research Site", "city": "Penang", "country": "Malaysia"}, {"facility": "Research Site", "city": "Surco", "state": "Lima", "country": "Peru"}, {"facility": "Research Site", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Research Site", "city": "Lipa City", "state": "Batangas", "country": "Philippines", "geoPoint": {"lat": 13.9411, "lon": 121.1631}}, {"facility": "Research Site", "city": "Davao City", "country": "Philippines", "geoPoint": {"lat": 7.07306, "lon": 125.61278}}, {"facility": "Research Site", "city": "Iloilo City", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "Research Site", "city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Research Site", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Research Site", "city": "Bangkoknoi", "state": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.76266, "lon": 100.47798}}, {"facility": "Research Site", "city": "Naimuang", "state": "Nakhonratchasima", "country": "Thailand"}, {"facility": "Research Site", "city": "Hat Yai", "state": "Songkla", "country": "Thailand", "geoPoint": {"lat": 7.00836, "lon": 100.47668}}, {"facility": "Research Site", "city": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Research Site", "city": "Khon Kaen", "country": "Thailand", "geoPoint": {"lat": 16.44671, "lon": 102.833}}]}, "referencesModule": {"references": [{"pmid": "32718193", "type": "DERIVED", "citation": "Zhang O, Minku LL, Gonem S. Detecting asthma exacerbations using daily home monitoring and machine learning. J Asthma. 2021 Nov;58(11):1518-1527. doi: 10.1080/02770903.2020.1802746. Epub 2020 Aug 14."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study started with an enrolment visit, Visit 1, 1-7 days prior to Visit 2 (run-in). At Visit 2 patients had to have a reversibility of \u226512% relative to baseline and their pre-bronchodilatory Forced expiratory volume in one second (FEV1) had to be \u226550% of the predicted normal value.", "recruitmentDetails": "The first participant entered the study on 16 February 2009, and the last participant completed the study on 23 February 2011. A total of 3209 participants were enrolled at 148 centres in 13 countries in Asia, America and Europe, and 2091 participants who fulfilled the randomisation criteria were randomised.", "groups": [{"id": "FG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "FG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1049"}, {"groupId": "FG001", "numSubjects": "1042"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "956"}, {"groupId": "FG001", "numSubjects": "932"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "93"}, {"groupId": "FG001", "numSubjects": "110"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "26"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "34"}]}, {"type": "Incorrect Enrolment", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Study-Specific Discontinuation Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Safety Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "Severe Non-Compliance to Protocol", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "BG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1049"}, {"groupId": "BG001", "value": "1042"}, {"groupId": "BG002", "value": "2091"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.7", "lowerLimit": "16", "upperLimit": "84"}, {"groupId": "BG001", "value": "45.6", "lowerLimit": "16", "upperLimit": "85"}, {"groupId": "BG002", "value": "45.7", "lowerLimit": "16", "upperLimit": "85"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "722"}, {"groupId": "BG001", "value": "692"}, {"groupId": "BG002", "value": "1414"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "327"}, {"groupId": "BG001", "value": "350"}, {"groupId": "BG002", "value": "677"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study", "description": "Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid \\[GCS\\] treatment, hospitalization, or emergency room \\[ER\\] treatment.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "week 52", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1049"}, {"groupId": "OG001", "value": "1042"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}]}]}, {"type": "SECONDARY", "title": "Number of Asthma Exacerbations", "description": "Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Asthma exacerbations", "timeFrame": "up to 52 weeks", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1049"}, {"groupId": "OG001", "value": "1042"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "259"}, {"groupId": "OG001", "value": "363"}]}]}]}, {"type": "SECONDARY", "title": "Morning Peak Expiratory Flow (PEF)", "description": "The mean value from a 52-week treatment period.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter/minute (L/min)", "timeFrame": "52-week treatment period", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1034"}, {"groupId": "OG001", "value": "1026"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "331.8", "spread": "102.2"}, {"groupId": "OG001", "value": "324.7", "spread": "101.9"}]}]}]}, {"type": "SECONDARY", "title": "Evening PEF", "description": "The mean value from a 52-week treatment period.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1034"}, {"groupId": "OG001", "value": "1026"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "334.2", "spread": "102.6"}, {"groupId": "OG001", "value": "327.8", "spread": "103.1"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in One Second (FEV1)", "description": "The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter (L)", "timeFrame": "4, 12, 24, 36 and 52 weeks after randomization", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1049"}, {"groupId": "OG001", "value": "1042"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.258", "spread": "0.76", "lowerLimit": "NA", "upperLimit": "NA"}, {"groupId": "OG001", "value": "2.222", "spread": "0.77", "lowerLimit": "NA", "upperLimit": "NA"}]}]}]}, {"type": "SECONDARY", "title": "Use of As-needed Medication", "description": "The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "inhalations/day", "timeFrame": "52-week treatment period", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1032"}, {"groupId": "OG001", "value": "1026"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.21", "spread": "1.39"}, {"groupId": "OG001", "value": "1.46", "spread": "1.60"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Symptom Score", "description": "The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "52-week treatment period", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1034"}, {"groupId": "OG001", "value": "1025"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.12", "spread": "1.04"}, {"groupId": "OG001", "value": "1.22", "spread": "1.02"}]}]}]}, {"type": "SECONDARY", "title": "Nights With Awakening(s) Due to Asthma Symptoms", "description": "The mean value from the treatment period was presented here.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Nights With Awakening(s)", "timeFrame": "52-week treatment period", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1024"}, {"groupId": "OG001", "value": "1025"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.7", "spread": "27.1"}, {"groupId": "OG001", "value": "17.5", "spread": "27.2"}]}]}]}, {"type": "SECONDARY", "title": "The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations", "description": "Mild asthma exacerbation was defined as morning PEF \u226520% below baseline, daily as-needed medication use \u22652 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "up to 52 weeks", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1049"}, {"groupId": "OG001", "value": "1042"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "80"}]}]}]}, {"type": "SECONDARY", "title": "Symptom-free Days (no Symptoms and no Awakenings)", "description": "A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "symptom-free days", "timeFrame": "52-week treatment period", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1034"}, {"groupId": "OG001", "value": "1026"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45.5", "spread": "37.8"}, {"groupId": "OG001", "value": "41.6", "spread": "37.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of As-needed-free Days", "description": "An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of as-needed-free days", "timeFrame": "52-week treatment period", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1032"}, {"groupId": "OG001", "value": "1026"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "51.4", "spread": "36.7"}, {"groupId": "OG001", "value": "47.2", "spread": "36.7"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)", "description": "An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of asthma-control days", "timeFrame": "52-week treatment period", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1033"}, {"groupId": "OG001", "value": "1026"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41.7", "spread": "37.3"}, {"groupId": "OG001", "value": "37.9", "spread": "36.6"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Control Questionnaire (ACQ)", "description": "The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.", "populationDescription": "The analysis set for efficacy was based on the full analysis set (FAS) in line with the ICH E9 guideline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "4, 12, 24, 36 and 52 weeks after randomization", "groups": [{"id": "OG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed"}, {"id": "OG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1040"}, {"groupId": "OG001", "value": "1038"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.162", "spread": "0.78"}, {"groupId": "OG001", "value": "1.289", "spread": "0.75"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Symbicort SMART", "description": "Symbicort Turbuhaler 160/4.5 microgram (mcg) one inhalation twice daily (bid) + Symbicort Turbuhaler 160/4.5 mcg as needed", "seriousNumAffected": 41, "seriousNumAtRisk": 1049, "otherNumAffected": 279, "otherNumAtRisk": 1049}, {"id": "EG001", "title": "Symbicort+Terbutaline As Needed", "description": "Symbicort Turbuhaler 160/4.5 mcg one inhalation twice daily + terbutaline Turbuhaler 0.4 mg as needed", "seriousNumAffected": 74, "seriousNumAtRisk": 1042, "otherNumAffected": 293, "otherNumAtRisk": 1042}], "seriousEvents": [{"term": "Acute Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Angina Unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Coronary Artery Disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Cleft Lip", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Meniere's Disease", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Basedow's Disease", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Retinal Detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Abdominal Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Acute Abdomen", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Anal Fissure", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Colonic Polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Gastric Polyps", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Hernia Obstructive", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Hepatotoxicity", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Drug Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 1042}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 1042}]}, {"term": "Tracheobronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Upper Respiratory Tract Infection Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Acute Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Breast Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Bronchopneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "H1n1 Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Lower Respiratory Tract Infection Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Otitis Media Chronic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Pneumonia Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Septic Shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Tooth Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Varicella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Viral Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Traumatic Brain Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 1042}]}, {"term": "Foot Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Joint Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Lower Limb Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Muscle Strain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Patella Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Sternal Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Type 2 Diabetes Mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 1042}]}, {"term": "Diabetes Mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Intervertebral Disc Protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Rheumatoid Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Uterine Leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Breast Cancer In Situ", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Intestinal Adenocarcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Metastatic Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Rectal Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Abortion Spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Abortion Threatened", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Premature Baby", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Major Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Breast Calcifications", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Dysfunctional Uterine Bleeding", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}, {"term": "Endometriosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Infertility Male", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 1042}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 1042}]}, {"term": "Nasal Septum Deviation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1042}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1042}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 137, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 133, "numAtRisk": 1042}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 69, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 77, "numAtRisk": 1042}]}, {"term": "Viral Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 60, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 72, "numAtRisk": 1042}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 49, "numAtRisk": 1049}, {"groupId": "EG001", "numAffected": 58, "numAtRisk": 1042}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Russian Federation"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000013726", "term": "Terbutaline"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000013566", "term": "Sympathomimetics"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M16496", "name": "Terbutaline", "asFound": "Temodar", "relevance": "HIGH"}, {"id": "M21711", "name": "Budesonide", "relevance": "LOW"}, {"id": "M304", "name": "Formoterol Fumarate", "relevance": "LOW"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}]}}, "hasResults": true}